Capital & FinanceEvent: September 4, 2026
Glafabra Therapeutics is considering a capital raise under Regulation Crowdfunding.
Published
Signal category
Capital & Finance
Quote
“We are considering a capital raise and are ”
— Glafabra Therapeutics team
Company
Glafabra Therapeutics
Gene therapy for Fabry and other enzyme deficiencies - one dose for years long durability and patient freedom
- Industry
- Biotechnology Research
- Company size
- 8 employees
Glafabra is a biotherapeutics development company focused on bringing into the clinic our Live-cel(TM) technology for cell-based gene therapy (Cb-GT). Our approach for Fabry Disease provides a 130x improvement in effectiveness for patients, when compared to the standard of care of enzyme replacement therapy. We are bringing to the clinic a therapy that is long acting. Where just one dose, can last for years, not weeks.